Navigation Links
Intrexon and Rentokil Enter into Research and Development Agreement to Explore a New Generation of Highly-Effective, Sustainable Pest Controls
Date:9/13/2013

GERMANTOWN, Md., Sept. 13, 2013 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has agreed to a joint research and development initiative with Rentokil Initial PLC that may lead to a new generation of highly-effective and sustainable pest control product and solution.

Under the agreement, Intrexon will apply its biology and science expertise to assist Rentokil in the development of specific pest control products.  The companies will also consider exploring additional areas of commercial product research and development.  Additional terms of the agreement were not disclosed.

Intrexon's Chief Operating Officer, Krish Krishnan, said Rentokil's long history of developing innovative pest control products is invaluable to the collaboration.

"Intrexon and Rentokil share a common DNA: an unwavering commitment to producing ground-breaking solutions," Krishnan said. "The same biotechnologies that have served and benefitted our collaborations in Health and Food will be equally valuable towards advancing our goals in Intrexon's emerging Environment group."

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and the Environment to create biologically based products that improve the quality of life and health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with commercial-scale design and development of complex biological systems.  The UltraVector® platform enables unprecedented control over the quality, function, and performance of living cells for a wide variety of
'/>"/>

SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
2. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
3. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
4. Intrexon Organizes Around New Synthetic Biology Markets
5. Intrexon Announces Filing of Registration Statement For Proposed Initial Public Offering
6. Intrexon Prices Initial Public Offering
7. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
8. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
9. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
10. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
11. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) reported total ... were $4.4 million, compared to $8.0 million during the same ... quarter was $8.9 million, or $0.23 per basic and diluted ... same period in 2014, of $8.7 million, or $0.27 per ... cash, cash equivalents and investments totaled $117.5 million. , ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Biodata, ... notebook with integrated protocols and specimen management systems, ... solutions and consulting services for life science research, ... of Labguru’s newest feature: chemical structure and reaction ... features for biologists, bio-chemists, and more, the integration ...
(Date:4/30/2015)... -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") ... services provider, today announced that its board of directors ... 29, 2015, from a consortium (the "Consortium") led by ... and chief executive officer of the Company, and Ally ... (the "Transaction") involving the acquisition of all outstanding shares ...
(Date:4/30/2015)... April 30, 2015 Sterlitech is ... membranes, the PX, PY, and PZ Polyacrylonotrile ... and disks. Designed to be ideal for ... membranes can fill critical process requirements where the ... processes. , “New regulations on industrial wastewater discharge ...
Breaking Biology Technology:Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Sterlitech Offers New Ultrafiltration Membranes 2
... ALEXANDRIA, Va., Dec. 9 First Coast Service Options ... in Medicare reimbursement solutions, to support a new Medicare ... Medicaid Services (CMS). , , ... disputes beginning Jan. 1, 2009 between health care providers ...
... Delcath Systems, Inc. (Nasdaq: DCTH ) today announced ... Directors. Dr. Stoll is Executive Chairman of Cortex Pharmaceuticals, Inc. ... treatment of central nervous system disorders. , ... , Prior to joining Cortex, Dr. ...
... CHESHIRE, Conn., Dec. 9 Soliris(R) (eculizumab),a terminal complement ... ), was observed by investigators to reduce blood measures,associated ... PNH. , A ... indicators of,pulmonary artery hypertension (PAH) in patients with paroxysmal ...
Cached Biology Technology:FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 2Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 3Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 4Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 5Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 6Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 7Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 8
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... the impact of student research on life at American University,s ... Following a 2009 study at American University,s main dining ... dishes used when trays were removed, trays have mostly gone ... the first time, a new paper coauthored by AU professor ...
... Houston faculty members have been named Charter Fellows of ... contributions to scientific and technological innovation. UH faculty ... Paul Chu, a physics professor and chief scientist of ... Dan Luss, a professor in chemical and biomedical engineering, ...
... (H2S) may play a wide-ranging role in staving off ... print in the journal Molecular and Cellular Biology ... explores the compound,s plethora of potential anti-aging pathways. ... important endogenous signaling molecule because of its significant effects ...
Cached Biology News:Going trayless study shows student impact 2Going trayless study shows student impact 3National Academy of Inventors honors 3 University of Houston professors 2National Academy of Inventors honors 3 University of Houston professors 3Hydrogen sulfide: The next anti-aging agent? 2
... Diluted Antiserum for RIA, Host: Rabbit ... Immunology Products, Host: Rabbit Antigen ... peptide and 1 2 ... (rat) (H-9295) and ([ 1 2 ...
...
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
... EnzChek Pyrophosphate Detection Kit,provides a fast, ... the inorganic pyrophosphate (PPi ) produced,by ... as DNA and,RNA polymerizations, cyclic AMP ... the enzymatic activation of fatty acids ...
Biology Products: